Menu

Refunds Coming to Theranos’s Arizona Customers

The blood-testing startup settles a legal dispute with the Arizona attorney general’s office.

Apr 20, 2017
Bob Grant

WIKIMEDIA, JHEUSERA day after diagnostics company Theranos announced that it had reached a settlement with the Centers for Medicare and Medicaid Services (CMS) involving conditions at its blood-testing labs in California, the company said that it had resolved another legal battle. On Tuesday (April 18), Theranos said that would be returning more than $4.5 million to Arizona consumers, to reimburse them for blood-testing services they had purchased through the firm between 2013 and 2016.

“Everyone who paid for a test will receive a full refund, period,” Mark Brnovich, the Arizona attorney general who was pursuing legal action against Theranos—alleging that the company misrepresented the methodology, accuracy, and reliability of the diagnostic tests it was selling—said in a statement.  “This is a great result and a clear message that Arizona’s consumer protection laws will be vigorously enforced.”

Theranos also agreed to pay $200,000 in civil penalties to the state of Arizona and $25,000 in lawyer’s fees. Further, the firm will not operate any kind of laboratory in Arizona for a period of two years, backdated to March 28, 2017.

According to a statement released by Theranos, the company’s Arizona settlement “demonstrated the company’s commitment to resolving the issue amicably on behalf of Arizonans and working collaboratively with state officials.”

“With the agreement,” the statement continued, “both parties intend to resolve all existing or potential claims against Theranos, which settled the matter without any admission of liability.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.